Table 2. Association between baseline clinicopathologic characteristics and cumulative SCIS score in the total cohort.
| Variable | SCIS score | P value | |||
|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | ||
| Patients (n) | 326 | 579 | 445 | 153 | |
| Age (years), median (IQR) | 70 (64.0–77) | 70 (64.0–77.25) | 71 (65.0–78) | 73 (66.0–79) | 0.17 |
| Gender, n (%) | 0.032 | ||||
| Male | 281 (86.2) | 467 (80.7) | 346 (77.8) | 123 (80.4) | |
| Female | 45 (13.8) | 112 (19.3) | 99 (22.2) | 30 (19.6) | |
| Smoking status, n (%) | <0.01 | ||||
| Never | 120 (36.8) | 248 (42.8) | 215 (48.3) | 84 (54.9) | |
| Current | 94 (28.8) | 166 (28.7) | 124 (27.9) | 45 (29.4) | |
| Former | 112 (34.4) | 165 (28.5) | 106 (23.8) | 24 (15.7) | |
| Cigarettes per day, median (IQR) | 10 (0–15) | 10 (0–15) | 10 (0–20) | 14 (0–25) | <0.01 |
| Duration of smoking (years), median (IQR) | 18 (0–30) | 18 (0–30) | 20 (0–30) | 30 (0–40) | <0.01 |
| Statin use, n (%) | 0.10 | ||||
| Never | 248 (76.1) | 436 (75.3) | 309 (69.4) | 109 (71.2) | |
| Current | 78 (23.9) | 143 (24.7) | 136 (30.6) | 44 (28.8) | |
| Multifocal disease, n (%) | 120 (36.8) | 240 (41.5) | 229 (51.5) | 76 (49.7) | <0.01 |
| Tumor size ≥3 cm, n (%) | 200 (61.3) | 360 (62.2) | 300 (67.6) | 101 (66.0) | 0.20 |
| Carcinoma in situ, n (%) | 56 (17.2) | 85 (14.7) | 64 (14.4) | 26 (17.0) | 0.64 |
| ESR (mm/h), median (IQR) | 11 (6.0–17) | 12 (7.0–19) | 14 (9.0–24) | 21 (12.5–27) | <0.01 |
| CRP (mg/L), median (IQR) | 1.05 (0.40–2.46) | 1.48 (0.5–5) | 3 (0.91–12) | 13.9 (12.0–16) | <0.01 |
SCIS, systemic cumulative inflammation score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.